每经AI快讯,4月1日,百利天恒(688506.SH)公告称,公司近日收到国家药监局签发的2个《药物临床试验批准通知书》,公司自主研发的创新生物药iza-bren(EGFR×HER3双抗ADC)的2个联合用药方案获得批准。获批适应症包括:联合阿比特龙±奥拉帕利、联合奥拉帕利用于去势抵抗性前列腺癌;联合贝伐珠单抗±化疗、联合奥拉帕利±贝伐珠单抗±化疗用于晚期卵巢癌。目前,该药物已有7项适应症被纳入...
Source Link每经AI快讯,4月1日,百利天恒(688506.SH)公告称,公司近日收到国家药监局签发的2个《药物临床试验批准通知书》,公司自主研发的创新生物药iza-bren(EGFR×HER3双抗ADC)的2个联合用药方案获得批准。获批适应症包括:联合阿比特龙±奥拉帕利、联合奥拉帕利用于去势抵抗性前列腺癌;联合贝伐珠单抗±化疗、联合奥拉帕利±贝伐珠单抗±化疗用于晚期卵巢癌。目前,该药物已有7项适应症被纳入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.